Company Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.
The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Adrian H. Gottschalk |
Contact Details
Address: 99 Coolidge Avenue, Suite 500 Watertown, Massachusetts 02472 United States | |
| Phone | 617-586-3100 |
| Website | foghorntx.com |
Stock Details
| Ticker Symbol | FHTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001822462 |
| CUSIP Number | 344174107 |
| ISIN Number | US3441741077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karin Hellsvik | Chief of Staff to the Chief Executive Officer, Vice President, Head of Corporate Affairs, Investor Relations and Operations |
| Adrian H. B. Gottschalk | President, Chief Executive Officer and Director |
| Dr. Anna Rivkin Ph.D. | Chief Business Officer |
| Dr. Gerald R. Crabtree M.d. | Founder and Member of Scientific Advisory Board |
| Ryan D. Maynard | Chief Financial Officer |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer |
| Michael J. LaCascia J.D. | Chief Legal Officer |
| Saurabh Sewak Ph.D. | Vice President of Corporate Development |
| Carlos Costa | Chief People Officer |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | 8-K | Current Report |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |
| Feb 23, 2026 | 8-K | Current Report |
| Jan 13, 2026 | SCHEDULE 13D/A | Filing |
| Jan 12, 2026 | 424B5 | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 4, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 8-K | Current Report |